6.95
0.07 (1.02%)
| Penutupan Terdahulu | 6.88 |
| Buka | 6.92 |
| Jumlah Dagangan | 661,480 |
| Purata Dagangan (3B) | 1,158,036 |
| Modal Pasaran | 647,835,328 |
| Harga / Pendapatan (P/E Ke hadapan) | 54.05 |
| Harga / Jualan (P/S) | 0.570 |
| Harga / Buku (P/B) | 1.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -12.20% |
| Margin Operasi (TTM) | -14.80% |
| EPS Cair (TTM) | -1.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.36% |
| Nisbah Semasa (MRQ) | 1.90 |
| Aliran Tunai Operasi (OCF TTM) | -6.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 18.68 M |
| Pulangan Atas Aset (ROA TTM) | -5.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Myriad Genetics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.30 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.77% |
| % Dimiliki oleh Institusi | 104.21% |
| Julat 52 Minggu | ||
| Median | 8.50 (22.30%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2025 | 8.50 (22.30%) | Beli | 6.68 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HAAS KEVIN RICHARD | 5.47 | - | 23,697 | 129,623 |
| MUZZEY DALE | 5.47 | - | 23,697 | 129,623 |
| VERRATTI MARK | 5.47 | - | 32,810 | 179,471 |
| WHEELER BENJAMIN RICHARD | 5.47 | - | 4,994 | 27,317 |
| Jumlah Keseluruhan Kuantiti Bersih | 85,198 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 466,033 | |||
| Purata Pembelian Keseluruhan ($) | 5.47 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MUZZEY DALE | Pegawai | 02 Feb 2026 | Diperolehi (+) | 23,697 | 5.47 | 129,623 |
| HAAS KEVIN RICHARD | Pegawai | 02 Feb 2026 | Diperolehi (+) | 23,697 | 5.47 | 129,623 |
| WHEELER BENJAMIN RICHARD | Pegawai | 02 Feb 2026 | Diperolehi (+) | 4,994 | 5.47 | 27,317 |
| VERRATTI MARK | Pegawai | 02 Feb 2026 | Diperolehi (+) | 32,810 | 5.47 | 179,471 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data |
| 12 Jan 2026 | Pengumuman | Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance |
| 05 Jan 2026 | Pengumuman | Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 09 Dec 2025 | Pengumuman | Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium |
| 25 Nov 2025 | Pengumuman | Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health |
| 11 Nov 2025 | Pengumuman | Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences |
| 10 Nov 2025 | Pengumuman | Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |